Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 9, 2016, Pages 1069-1074

  Kim, Jae Hyun ^a   Cheon, Jae Hee ^a   Park, Yehyun ^a   Lee, Hyun Jung ^a   Park, Soo Jung ^a   Kim, Tae Il ^a   Kim, Won Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Clinical relapse; clinical remission; mucosal healing; prognosis; ulcerative colitis

Indexed keywords

AZATHIOPRINE; BIOLOGICAL PRODUCT; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE DURATION; FAMILY HISTORY; FEMALE; FOLLOW UP; HEALING; HUMAN; MAJOR CLINICAL STUDY; MALE; MAYO ENDOSCOPIC SUBSCORE; MEDICAL RECORD REVIEW; MUCOSAL HEALING; PATIENT HISTORY OF SURGERY; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DISEASE COURSE; DRUG EFFECTS; INTESTINE MUCOSA; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; VERY ELDERLY; WOUND HEALING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; COLITIS, ULCERATIVE; COLONOSCOPY; DISEASE PROGRESSION; FEMALE; HUMANS; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; MALE; MESALAMINE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WOUND HEALING; YOUNG ADULT;

EID: 84958757305     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2016.1150503     Document Type: Article

References (45)

1. A.Kornbluth, D.B.Sachar Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–1385.
2. A.Dignass, R.Eliakim, F.Magro, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.
3. S.Danese, C.Fiocchi Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12:4807–4812.
4. H.S.de Souza, C.Fiocchi Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
5. A.Dignass, J.O.Lindsay, A.Sturm, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030.
6. K.F.Froslie, J.Jahnsen, B.A.Moum, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–422.
7. J.F.Colombel, P.Rutgeerts, W.Reinisch, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–1201.
8. S.C.Truelove, L.J.Witts Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.
9. S.P.Travis, D.Schnell, P.Krzeski, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535–542.
10. K.T.Thia, E.V.LoftusJr., D.S.Pardi, et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011;17:1257–1264.
11. K.W.Schroeder, W.J.Tremaine, D.M.Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.
12. J.H.Baron, A.M.Connell, J.E.Lennard-Jones Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:89–92.
13. W.J.Sandborn, P.Rutgeerts, B.G.Feagan, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–1260. quiz 520.
14. P.Rutgeerts, W.J.Sandborn, B.G.Feagan, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
15. G.Meucci, R.Fasoli, S.Saibeni, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis. 2012;18:1006–1010.
16. J.E.Baars, V.J.Nuij, B.Oldenburg, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18:1634–1640.
17. L.Rosenberg, G.O.Lawlor, T.Zenlea, et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013;19:779–784.
18. P.Boal Carvalho, F.Dias de Castro, B.Rosa, et al. Mucosal healing in ulcerative colitis – when zero is better. J Crohns Colitis. 2016;10:20–25.
19. M.Barreiro-de Acosta, N.Vallejo, D.de la Iglesia, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study. J Crohns Colitis. 2016;10:13–19.
20. D.Laharie, J.Filippi, X.Roblin, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther. 2013;37:998–1004.
21. G.D’Haens, W.J.Sandborn, B.G.Feagan, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786.
22. M.H.Vatn Mucosal healing: impact on the natural course or therapeutic strategies. Dig Dis. 2009;27:470–475.
23. P.Rutgeerts, R.H.Diamond, M.Bala, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006;63:433–442. quiz 64.
24. V.Annese, M.Daperno, M.D.Rutter, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018.
25. S.Ardizzone, A.Cassinotti, P.Duca, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483–489.e3.
26. A.Nakarai, J.Kato, S.Hiraoka, et al. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol. 2014;20:18367–18374.
27. M.D.Rutter, B.P.Saunders, K.H.Wilkinson, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–1816.
28. A.Zahn, U.Hinz, M.Karner, et al. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. Inflamm Bowel Dis. 2006;12:1058–1067.
29. K.Yokoyama, K.Kobayashi, M.Mukae, et al. Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis. Gastroenterol Res Pract. 2013;2013:192794.
30. S.J.Park, W.H.Kim, J.H.Cheon Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol. 2014;20:11525–11537.
31. S.H.Park, Y.M.Kim, S.K.Yang, et al. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007;13:278–283.
32. K.L.Ling, C.J.Ooi, W.Luman, et al. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J Clin Gastroenterol. 2002;35:144–148.
33. K.H.Lok, H.G.Hung, C.H.Ng, et al. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol. 2008;23:406–410.
34. S.Yamaguchi, Y.Takeuchi, K.Arai, et al. Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol. 2016;31:93–98.
35. S.Yamada, T.Yoshino, M.Matsuura, et al. Efficacy and safety of long-term thiopurine maintenance treatment in Japanese patients with ulcerative colitis. Intest Res. 2015;13:250–258.
36. Y.S.Jung, D.I.Park, Y.H.Kim, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705–1712.
37. Y.Suzuki, S.Motoya, H.Hanai, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283–294.
38. K.M.Lee, Y.T.Jeen, J.Y.Cho, et al. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol. 2013;28:1829–1833.
39. J.H.Choi, E.S.Kim, K.B.Cho, et al. Old age at diagnosis is associated with favorable outcomes in Korean patients with inflammatory bowel disease. Intest Res. 2015;13:60–67.
40. I.Monstad, O.Hovde, I.C.Solberg, et al. Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Ann Gastroenterol. 2014;27:95–104.
41. J.H.Lee, J.H.Cheon, C.M.Moon, et al. Do patients with ulcerative colitis diagnosed at a young age have more severe disease activity than patients diagnosed when older? Digestion. 2010;81:237–243.
42. E.S.Jang, D.H.Lee, J.Kim, et al. Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. Hepatogastroenterology. 2009;56:1304.
43. M.Waterman, J.Knight, A.Dinani, et al. Predictors of outcome in ulcerative colitis. Inflamm Bowel Dis. 2015;21:2097–2105.
44. S.Danese, L.Vuitton, L.Peyrin-Biroulet Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–545.
45. B.G.Levesque, W.J.Sandborn, J.Ruel, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015;148:37–51.e1.